search
Back to results

Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control (RESONATE)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Active
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Problem Solving Treatment for Diabetes
Attention Control Group
Sponsored by
Singapore Eye Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes, problem solving treatment, HbA1c, sugar control

Eligibility Criteria

21 Years - 110 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with type 2 diabetes and at least 1 recent reading of suboptimal glycaemic control (HbA1c ≥7.0%) Able to speak English and/or Mandarin Singapore citizens or those with Singapore permanent residency status Aged 21 years and above No cognitive impairment, as assessed using the 6-item Cognitive Impairment Test (6CIT) Adequate hearing with/without hearing aids to respond to normal conversation Consent to participate in the sessions if randomised to the PST-D treatment arm Exclusion Criteria: Have hearing or cognitive impairment compromising consent or study procedures All recent HbA1c readings are <7.0% Uncontactable or unwilling/unable to participate in all the PST-D sessions if randomised to the PST-D group

Sites / Locations

  • Singapore Eye Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention Group (PST-D)

Attention control group

Arm Description

Participants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.

The participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.

Outcomes

Primary Outcome Measures

Change in HbA1c over 18 months
Blood test

Secondary Outcome Measures

Change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides over 18 months
Blood tests
Incidence and progression of diabetic retinopathy
Grading of digital retinal photographs and spectral-domain optical coherence tomography scans
Incidence and progression of diabetic nephropathy
Blood tests results of epidermal growth factor receptor from serum creatinine and estimated using the CKD-EPI equation
Incidence and progression of diabetic peripheral neuropathy
Semmes-Weinstein monofilament examination (SWME) results
Incidence and progression of distance visual impairment
Pinhole visual acuity values
Change in diabetes self-efficacy over 18 months
Perceived Diabetes Self-management scale. Minimum value: 8 Maximum value: 40 Higher scores indicate more confidence in self-managing one's diabetes.
Change in problem-focused coping self-efficacy over 18 months
Problem-Focusing subscale from Coping Self-Efficacy Scale Minimum value: 0 Maximum value: 120 Higher scores indicate higher level of problem-focused coping self-efficacy.
Change in diabetes self-care activities over 18 months
Diabetes Self-management Questionnaire Minimum value: 0 Maximum value: 12 Higher values indicate more effective self-care.
Change in medication taking behaviour over 18 months
Domains of Subjective Extent of Nonadherence It comprises two domains - the extent of and reasons for medication non-adherence over the past 7 days. For the Extent of Non-Adherence domain, the overall score is calculated by the average score of the three items, with higher scores indicating greater levels of non-adherence (Minimum value: 0; Maximum value: 4). There are 18 items in the Reasons for Non-Adherence domain which stand on their own as descriptors. The reasons scale is a causal indicator model and higher scores indicate greater endorsement of each reason for non-adherence (Minimum value: 0; Maximum value: 4).
Change in diabetes-related quality of life over 18 months
Asian Diabetes Quality of Life Minimum value: 18 (English version); 15 (Chinese version) Maximum value: 105 (English version); 90 (Chinese version) Higher scores indicate better quality of life.
Cost-effectiveness of PST-D
EQ-5D-5L There are five dimensions in the EQ-5D-5L descriptive system - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to the five dimensions are used to calculate an index score ranging from -0.59 for the worst health state to 1.00 for perfect health. A score of 0 represents death and a negative score indicates a state worse than death.

Full Information

First Posted
December 1, 2022
Last Updated
December 12, 2022
Sponsor
Singapore Eye Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05651490
Brief Title
Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control
Acronym
RESONATE
Official Title
RESONATE: A Randomised Controlled Trial of Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 9, 2020 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Singapore Eye Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this randomised controlled trial is to test a cognitive-behavioural intervention, Problem Solving Treatment for Diabetes (PST-D) in patients with type 2 diabetes. The main questions it aims to answer are: To evaluate the clinical effectiveness of PST-D compared with the attention control group. To determine the impact of PST-D on patient-centred, behavioural, and psychosocial outcomes. To identify independent factors associated with an improvement in HbA1c and reductions in incidence and progression diabetic retinopathy, diabetic neuropathy, diabetic peripheral neuropathy, and visual impairment at 18-month follow-up in both groups; and determine if these factors mediate the associations between the PST-D intervention with the above outcomes. To quantify the incremental cost-effectiveness of PST-D compared with the attention control group at 18-month follow-up. To understand participants' views, experiences, and opinions about PST-D; and the barriers and facilitators to program completion. Participants will complete blood tests, ocular examinations, and a series of questionnaires at baseline, 6-month, 12-month, and 18-month follow-up. Participants will also complete the intervention/ control group sessions conducted over the phone, video call, or face-to-face depending on the participant's preference. Researchers will compare the intervention group against the attention control group to determine the effectiveness of PST-D on improving clinical, patient-centred, behavioural, and psychosocial outcomes.
Detailed Description
Assuming the recent rise in obesity prevalence persists, the lifetime risk of diabetes in Singapore will almost double by 2050. Poorly controlled diabetes leads to various diabetes-related complications which may consequently require costly lifelong treatment and have a profound impact on patients' quality of life. Based on a previous trial on problem solving therapy in people with diabetic retinopathy and significant levels of distress, the investigators have designed a cognitive-behavioural intervention which aims to teach individuals skills to cope with and solve problems related to diabetes self-management. This novel intervention will be carried out at one tertiary hospital in Singapore, with the option for interested community-dwelling individuals with diabetes to participate, to facilitate its implementation and transition to the real world setting to assist patients with diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes, problem solving treatment, HbA1c, sugar control

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomly allocated to one of the two arms: intervention group (PST-D) and attention control group. The random assignment will be based on a code generated by R statistical software, contained within sequential sealed envelopes. The random number sequence will be password protected and available to a statistician external to the study team who will conduct the randomisation process. The randomisation process is designed to yield an expected assignment ratio of 1:1
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
106 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group (PST-D)
Arm Type
Experimental
Arm Description
Participants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
Arm Title
Attention control group
Arm Type
Active Comparator
Arm Description
The participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
Intervention Type
Behavioral
Intervention Name(s)
Problem Solving Treatment for Diabetes
Intervention Description
In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable. During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving: Clarifying and defining the problem Setting a realistic goal Brainstorming multiple solutions Generating pros and cons for each solution Evaluating and choosing a preferred solution Developing a specific action plan to implement the solution Evaluating outcomes from the previous session. Participants will also plan to engage in at least 1 enjoyable activity daily during the week. The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills. Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants.
Intervention Type
Behavioral
Intervention Name(s)
Attention Control Group
Intervention Description
During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
Primary Outcome Measure Information:
Title
Change in HbA1c over 18 months
Description
Blood test
Time Frame
Baseline, 6-month, 12-month, 18-month
Secondary Outcome Measure Information:
Title
Change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides over 18 months
Description
Blood tests
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Incidence and progression of diabetic retinopathy
Description
Grading of digital retinal photographs and spectral-domain optical coherence tomography scans
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Incidence and progression of diabetic nephropathy
Description
Blood tests results of epidermal growth factor receptor from serum creatinine and estimated using the CKD-EPI equation
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Incidence and progression of diabetic peripheral neuropathy
Description
Semmes-Weinstein monofilament examination (SWME) results
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Incidence and progression of distance visual impairment
Description
Pinhole visual acuity values
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Change in diabetes self-efficacy over 18 months
Description
Perceived Diabetes Self-management scale. Minimum value: 8 Maximum value: 40 Higher scores indicate more confidence in self-managing one's diabetes.
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Change in problem-focused coping self-efficacy over 18 months
Description
Problem-Focusing subscale from Coping Self-Efficacy Scale Minimum value: 0 Maximum value: 120 Higher scores indicate higher level of problem-focused coping self-efficacy.
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Change in diabetes self-care activities over 18 months
Description
Diabetes Self-management Questionnaire Minimum value: 0 Maximum value: 12 Higher values indicate more effective self-care.
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Change in medication taking behaviour over 18 months
Description
Domains of Subjective Extent of Nonadherence It comprises two domains - the extent of and reasons for medication non-adherence over the past 7 days. For the Extent of Non-Adherence domain, the overall score is calculated by the average score of the three items, with higher scores indicating greater levels of non-adherence (Minimum value: 0; Maximum value: 4). There are 18 items in the Reasons for Non-Adherence domain which stand on their own as descriptors. The reasons scale is a causal indicator model and higher scores indicate greater endorsement of each reason for non-adherence (Minimum value: 0; Maximum value: 4).
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Change in diabetes-related quality of life over 18 months
Description
Asian Diabetes Quality of Life Minimum value: 18 (English version); 15 (Chinese version) Maximum value: 105 (English version); 90 (Chinese version) Higher scores indicate better quality of life.
Time Frame
Baseline, 6-month, 12-month, 18-month
Title
Cost-effectiveness of PST-D
Description
EQ-5D-5L There are five dimensions in the EQ-5D-5L descriptive system - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to the five dimensions are used to calculate an index score ranging from -0.59 for the worst health state to 1.00 for perfect health. A score of 0 represents death and a negative score indicates a state worse than death.
Time Frame
Baseline, 6-month, 12-month, 18-month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
110 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with type 2 diabetes and at least 1 recent reading of suboptimal glycaemic control (HbA1c ≥7.0%) Able to speak English and/or Mandarin Singapore citizens or those with Singapore permanent residency status Aged 21 years and above No cognitive impairment, as assessed using the 6-item Cognitive Impairment Test (6CIT) Adequate hearing with/without hearing aids to respond to normal conversation Consent to participate in the sessions if randomised to the PST-D treatment arm Exclusion Criteria: Have hearing or cognitive impairment compromising consent or study procedures All recent HbA1c readings are <7.0% Uncontactable or unwilling/unable to participate in all the PST-D sessions if randomised to the PST-D group
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ecosse Lamoureux, PhD
Organizational Affiliation
Singapore Eye Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Singapore Eye Research Institute
City
Singapore
ZIP/Postal Code
169856
Country
Singapore

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control

We'll reach out to this number within 24 hrs